BAVARIAN NORDIC/S (OTCMKTS:BVNRY) Rating Increased to Hold at Zacks Investment Research

Share on StockTwits

Zacks Investment Research upgraded shares of BAVARIAN NORDIC/S (OTCMKTS:BVNRY) from a sell rating to a hold rating in a report released on Monday, Zacks.com reports.

According to Zacks, “Bavarian Nordic A/S is a biotechnology company. It focused on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases. The company’s product pipeline consists of IMVAMUNE(R), PROSTVAC (R), MVA-BN Brachyury, CV-301, MVA-BN Filo which are in clinical trial stage. Bavarian Nordic A/S is headquartered in Kvistgaard, Denmark. “

Shares of OTCMKTS BVNRY opened at $9.03 on Monday. The stock has a market cap of $843.29 million, a price-to-earnings ratio of -15.31 and a beta of 0.60. The company has a current ratio of 7.93, a quick ratio of 7.52 and a debt-to-equity ratio of 0.23. BAVARIAN NORDIC/S has a 1-year low of $5.92 and a 1-year high of $9.31. The stock’s 50-day moving average is $8.74 and its 200 day moving average is $7.75.

BAVARIAN NORDIC/S (OTCMKTS:BVNRY) last announced its quarterly earnings data on Thursday, August 15th. The company reported ($0.16) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.13) by ($0.03). The firm had revenue of $15.26 million for the quarter, compared to analysts’ expectations of $19.80 million. BAVARIAN NORDIC/S had a negative net margin of 42.42% and a negative return on equity of 12.47%. On average, analysts forecast that BAVARIAN NORDIC/S will post -0.56 EPS for the current fiscal year.

About BAVARIAN NORDIC/S

Bavarian Nordic A/S, a biotechnology company, develops, manufactures, and commercializes a portfolio of cancer immunotherapies and vaccines for infectious diseases. The company markets non-replicating smallpox vaccine under the IMVAMUNE and IMVANEX names. It is also developing MVA-BN RSV, which is in Phase II clinical trials development stage for the prevention of respiratory syncytial virus; MVA-BN Filo that is in Phase III clinical trials for the treatment of Ebola and Marburg; and MVA-BN HPV that is in Phase I/IIa clinical trials to treat human papillomavirus.

Featured Story: Cost of Capital Explained

Get a free copy of the Zacks research report on BAVARIAN NORDIC/S (BVNRY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for BAVARIAN NORDIC/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BAVARIAN NORDIC/S and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

SOTHERLY HOTELS/SH SH  Upgraded by Zacks Investment Research to Hold
SOTHERLY HOTELS/SH SH Upgraded by Zacks Investment Research to Hold
Solaredge Technologies  Lowered to Hold at Zacks Investment Research
Solaredge Technologies Lowered to Hold at Zacks Investment Research
Resonant  Upgraded to “Hold” at Zacks Investment Research
Resonant Upgraded to “Hold” at Zacks Investment Research
Portola Pharmaceuticals  PT Lowered to $44.00
Portola Pharmaceuticals PT Lowered to $44.00
UltraNote Coin Reaches Market Cap of $13,486.00
UltraNote Coin Reaches Market Cap of $13,486.00
FS KKR Capital Corp  Receives $7.63 Consensus PT from Analysts
FS KKR Capital Corp Receives $7.63 Consensus PT from Analysts


© 2006-2019 Ticker Report